focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

Fri, 15th Dec 2023 16:51

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

The FTSE 100 index gave back 72.62 points, 1.0%, at 7,576.36. It had surged more than 100 points on Thursday.

The FTSE 250 lost 47.99 points, 0.3%, at 19,208.97, though the AIM All-Share ended up 1.47 points, 0.2%, at 739.31.

For the week, the FTSE 100 rose 0.3%, the FTSE 250 added 2.7%, while the AIM All-Share climbed 2.2%.

The Cboe UK 100 ended down 1.0% at 756.32. The Cboe UK 250 lost 0.4% at 16,658.06, though the Cboe Small Companies added 1.2% at 14,297.15.

In European equities on Friday, the CAC 40 in Paris closed up 0.3%, while the DAX 40 in Frankfurt ended flat.

"After the euphoria of the Powell pivot party on Wednesday we got a wake-up call from New York Fed President John Williams when he pushed back on market expectations of a March rate cut saying it was premature to be even considering anything like that. Given the sharp move in bond markets since Wednesday it was perhaps felt necessary to pour a little cold water on the moves of the last 48 hours, with Williams sent out to say it was premature to be thinking in terms of rate cuts. That's not to say they wouldn't happen next year but to be pricing in between 5-6 rate cuts next year as markets appeared to be doing seems to be a case of getting a little carried away," CMC Markets analyst Michael Hewson commented.

The Fed left its benchmark interest rate unchanged, as expected on Wednesday, but signalled rate cuts of as much as 75 basis points in the coming year.

The decision from the Federal Open Market Committee extends a pause in monetary policy that has been in place since July, leaving the federal funds rate at a 22-year high of 5.25% to 5.5%.

But the latest quarterly dot plot showed that most officials expect rates to be in the range of 4.4% to 4.9% by the end of 2024.

A small majority of the Federal Open Market Committee anticipate at least three quarter-point cuts from current levels.

In New York, both the Dow Jones Industrial Average and the S&P 500 were up 0.1%, while the Nasdaq Composite climbed 0.5%.

Analysts at Tower Bridge Advisors commented: "Markets expect it in March although Fed officials don't universally agree. The question for investors is how much of the good news is already priced in. Right now, momentum firmly favours the bulls. That could change quickly once Christmas is over."

The pound was quoted at USD1.2693 at the time of the London equities close on Friday, lower compared to USD1.2762 on Thursday. The euro stood at USD1.0912, lower against USD1.0994. Against the yen, the dollar was trading at JPY141.75, higher compared to JPY141.60.

Shares in pharmaceutical firms struggled on Friday, putting some pressure on London's FTSE 100. AstraZeneca ended 2.7% lower, while GSK lost 2.9%.

Bloomberg on Thursday reported the likes of Astra and GSK have come under scrutiny from US Senator Elizabeth Warren.

The drugmakers have been accused of making sham patents to send prices higher and clip the wings of competition, the news agency reported.

Astra's Symbicort asthma treatment and GSK's Advair and Flovent pair of inhalers are among the products mentioned in a letter sent by Warren to the drugmakers.

Trainline shot up 11% as the threat from the UK government's Great British Railways offering subsided.

Trainline on Thursday noted the UK Department for Transport will no longer pursue creating a ticket retailing website and app, which would have presented competition for the FTSE 250 listing's eponymous platform.

The proposal for a Great British Railways app was first mooted in May 2021 as part of a white paper. GBR is a planned state-owned body that would oversee UK rail transport.

Shares in pub firm Marston's rose 5.3%, adding to Thursday's 6.6% stride. JPMorgan had lifted the stock to 'overweight' from 'neutral' on Thursday.

On AIM, Getech lost 27%.

The Leeds-based geo-energy and green hydrogen company said its client base, 85% of which is based outside of the UK, were showing a "growing level of caution" due to economic and geopolitical instability.

Getech said this has pushed a number of projects initially expected to begin before the end of 2023 into 2024.

As a result, Getech has warned that sales for the full year are not expected to surpass GBP4.4 million, down 14% from GBP5.1 million in 2022.

XLMedia shares slumped 12% after announcing that revenue for 2023 will fall shy.

The London-based global digital media company said that a "change in the revenue profile" of its North American activities had been caused by, among other things, the exit of XLMedia's major partner Barstool from the market.

The group's revenue for the full year is now expected in the range of USD50.0 to USD52.0 million, down from USD71.8 million in 2022. The group also predicted adjusted earnings before interest, tax, depreciation and amortisation of USD12 million to USD14 million, down from USD17.8 million in 2022.

Brent oil was quoted at USD76.34 a barrel late Friday in London, down from USD76.70 late Thursday. Gold was quoted at USD2,034.62 an ounce, down against USD2,039.11.

Monday's economic calendar has the latest Ifo business climate index reading from Germany at 0900 GMT. The week picks up speed with a rate decision from the Bank of Japan on Tuesday, UK inflation data on Wednesday, and a US gross domestic product reading on Thursday.

Monday's local corporate calendar has full-year results from ten-pin bowling firm Hollywood Bowl.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.